Comparison between brodalumab, secukinumab and ixekizumab effectiveness and drug survival: A real-life experience on 638 patients with psoriasis

Exp Dermatol. 2023 Sep;32(9):1591-1594. doi: 10.1111/exd.14874. Epub 2023 Jul 3.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal, Humanized* / therapeutic use
  • Humans
  • Psoriasis* / drug therapy
  • Severity of Illness Index
  • Treatment Outcome

Substances

  • ixekizumab
  • secukinumab
  • brodalumab
  • Antibodies, Monoclonal, Humanized